Gemcitabine treatment was also found to increase vascularity of tumours (increased CD31 per unit area) compared to controls, while HiCi treatment was associated with reduced vascularity, suggesting an anti-angiogenic effect (Figure 2c). The gene discussed is PECAM1; the disease is neoplasm.